What AI Driven Imaging Data Analysis Could Mean for Bio-Pharmaceutical R&D?
Dr Olga Kubassova, Scientific Founder and CEO of IAG, Image Analysis Group is invited to speak at the 6th Annual – Life Science, R&D Data Intelligence Leaders Forum, January 23-25, 2019, Basel, Switzerland.
Olga is a mathematician with expertise in actively managing innovation in life science companies, asset positioning, strategy and bio-pharma investment. Her expertise and domain knowledge are in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics.
In this talk, she will cover topics critical to successful bio-pharmaceutical drug development and early go / no go decision support:
- What AI Driven Imaging Data Analysis Could Mean for Bio-Pharmaceutical R&D?
- How AI and Machine Learning are Changing our Approach to the Assessment of Trial Outcomes?
- Getting AI into your R&D is Simple and Necessary
AI driven insights are very different from the traditional analytics as they are much more data intensive and detailed. With the rise of novel technologies, we have an opportunity to bring the power of machine learning and decision support to make objective, accurate and early decisions, especially at early stages of clinical development.
About Next Level Life Sciences
NextLevel Life Sciences is a leading, strategic business information provider and opportunity facilitator for the international life sciences industry. This event serves as a platform where senior executives, leading experts and key stakeholders meet together to share ideas, achieve critical insights and discover practical solutions to enhance medical innovation for patient benefit. To find out more about this conference click here.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin
Join us at BIO International Convention in Boston 5th-8th June 2023
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.